Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results, Beats Estimates By $0.04 EPS

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) announced its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.04, Zacks reports. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The firm had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.48 billion.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.3%

NYSE:FMS opened at $23.45 on Thursday. The firm has a market capitalization of $12.60 billion, a PE ratio of 12.15, a price-to-earnings-growth ratio of 4.36 and a beta of 0.77. The stock has a 50 day moving average of $23.96 and a 200-day moving average of $23.13. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.02 and a 52 week high of $27.64. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Analyst Ratings Changes

Several research analysts have recently commented on FMS shares. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research report on Friday, May 8th. Sanford C. Bernstein upped their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Truist Financial set a $25.00 price objective on Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, August 5th. BNP Paribas Exane downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a report on Tuesday, July 28th. Finally, Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Six analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $23.57.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 14.2% during the first quarter. AQR Capital Management LLC now owns 14,297 shares of the company’s stock valued at $356,000 after acquiring an additional 1,777 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 160.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 37,610 shares of the company’s stock worth $1,075,000 after acquiring an additional 23,163 shares during the period. American Century Companies Inc. increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% in the 2nd quarter. American Century Companies Inc. now owns 29,173 shares of the company’s stock worth $833,000 after acquiring an additional 5,127 shares during the period. Russell Investments Group Ltd. lifted its position in Fresenius Medical Care AG & Co. KGaA by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock valued at $146,000 after purchasing an additional 896 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 141.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,906 shares of the company’s stock valued at $83,000 after purchasing an additional 1,704 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.